Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acitretin

FDA-approved product (capsule, oral), marketed as Acitretin, Soriatane.

Registered studies
42
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Acitretin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Retinoids for treatment of psoriasis
FDA pharmacologic class
Retinoid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

42registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Acitretin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acitretin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis

    NCT00811005 · start 2008-10

    Registered record
    Registry ID
    NCT00811005
    Conditions
    Pustular Palmoplantar Psoriasis
    Interventions
    8-methoxypsoralen or 5- methoxypsoralen; 8-methoxypsoralen or 5methoxypsoralen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-10
    Completion
    2010-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPustular Palmoplantar Psoriasis
    Intervention8-methoxypsoralen or 5- methoxypsoralen; 8-methoxypsoralen or 5methoxypsoralen
    PhasePhase 3
    Registry statusUnknown

  • Spanish Registry of Systemic Treatments in Psoriasis

    NCT02075697 · start 2008-10

    Registered record
    Registry ID
    NCT02075697
    Conditions
    Psoriasis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2008-10
    Completion
    2025-10
    Enrolment
    3,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis

    NCT00707070 · start 2008-09

    Registered record
    Registry ID
    NCT00707070
    Conditions
    Chronic Plaque Psoriasis
    Interventions
    efalizumab plus placebo; efalizumab plus acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-09
    Completion
    2009-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Plaque Psoriasis
    Interventionefalizumab plus placebo; efalizumab plus acitretin
    PhasePhase 4
    Registry statusUnknown

  • Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis

    NCT01039142 · start 2008-03

    Registered record
    Registry ID
    NCT01039142
    Conditions
    Psoriasis
    Interventions
    Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-03
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionAcitretin
    PhasePhase 4
    Registry statusCompleted

  • Acitretin Plasma Levels Under Hemodialysis

    NCT00488384 · start 2007-06

    Registered record
    Registry ID
    NCT00488384
    Conditions
    Carcinoma, Squamous Cell
    Interventions
    Chemopreventive application (Acitretin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2007-06
    Completion
    2018-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Squamous Cell
    InterventionChemopreventive application (Acitretin)
    PhasePhase 4
    Registry statusWithdrawn

  • Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis

    NCT00395941 · start 2006-12

    Registered record
    Registry ID
    NCT00395941
    Conditions
    Psoriasis
    Interventions
    Pioglitazone; Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-12
    Completion
    2008-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionPioglitazone; Acitretin
    PhasePhase 2
    Registry statusCompleted

  • Acitretin and Etanercept in Psoriasis

    NCT00156247 · start 2005-09

    Registered record
    Registry ID
    NCT00156247
    Conditions
    Psoriasis
    Interventions
    acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2009-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    Interventionacitretin
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

    NCT00723437 · start 2005-01

    Registered record
    Registry ID
    NCT00723437
    Conditions
    Psoriasis
    Interventions
    acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-01
    Completion
    2008-07
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    Interventionacitretin
    PhasePhase 4
    Registry statusCompleted

  • Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer

    NCT00644384 · start 2003-02

    Registered record
    Registry ID
    NCT00644384
    Conditions
    Non-melanomatous Skin Cancer
    Interventions
    acitretin; gene expression analysis; northern blotting; polymerase chain reaction; protein expression analysis; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-02
    Completion
    2006-05
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-melanomatous Skin Cancer
    Interventionacitretin; gene expression analysis; northern blotting; polymerase chain reaction +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation

    NCT00003611 · start 2000-05

    Registered record
    Registry ID
    NCT00003611
    Conditions
    Non-melanomatous Skin Cancer
    Interventions
    acitretin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2000-05
    Completion
    2003-06
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-melanomatous Skin Cancer
    Interventionacitretin; placebo
    PhaseNot applicable
    Registry statusCompleted

  • The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases

    NCT00005660 · start 1977-10

    Registered record
    Registry ID
    NCT00005660
    Conditions
    Basal Cell Carcinoma; Keratosis Palmaris et Plantaris; Psoriasis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1977-10
    Completion
    2001-11
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasal Cell Carcinoma; Keratosis Palmaris et Plantaris; Psoriasis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

    NCT00002143

    Registered record
    Registry ID
    NCT00002143
    Conditions
    HIV Infections; Psoriasis
    Interventions
    Acitretin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Psoriasis
    InterventionAcitretin
    PhasePhase 3
    Registry statusCompleted